ACTRN12615001181594进行中(未招募)2 期
A Mulicentre Phase II clinical Trial of STereotactic Ablative Body Radiotherapy for Primary Kidney Cancer
Trans Tasman Radiation Oncology Group (TROG)0 个研究点目标入组 71 人开始时间: 2015年11月3日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 71
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit(—)
- 性别
- All
入选标准
- •1. Age > 18 years old
- •2. All patients must have a biopsy confirmed diagnosis of renal cell carcinoma with a single lesion within a kidney
- •3. ECOG performance of 0-2 inclusive.
- •4. Life expectancy > 9 months
- •5. Either medically inoperable, technically high risk for surgery or decline surgery.
- •6. Multidisciplinary decision for active treatment
排除标准
- •1. Cytotoxic chemotherapy within 3 weeks of commencement of treatment, or concurrently with treatment. Delivery of targeted agents (such as sunitinib) are allowable only when at least 7 days separate the delivery of the proposed agent and the delivery of the stereotactic radiotherapy.
- •2. Previous high-dose radiotherapy to an overlapping region
- •3. Tumours of larger than 8cm is size
研究者
相似试验
撤回
2 期
iver Image Guided High Dose Radiation Therapy for the Treatment of Colorectal Liver Metastasesiver metastases from colo-rectal cancerLiver metastases from colo-rectal cancerCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12613001066774Trans Tasman Radiation Oncology Group (TROG)30
招募中
不适用
A multicentre two-arm, phase II trial assessing the safety and efficacy of first-line lazertinib and locally ablative radiotherapy in patients with synchronous oligo-metastatic EGFR-mutant non-small cell lung cancerNeoplasmsKCT0006760Yonsei University Health System, Severance Hospital68
进行中(未招募)
1 期
A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients =60 years with AML not eligible for conventionalChemotherapyMedDRA - 10000886, akute myeloische Leukämie, acute myeloid leukemiaC92.0Acute myeloblastic leukaemia [AML]DRKS00000580niversität Leipzig13
进行中(未招募)
不适用
A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients =60 years with AML not eligible for conventionalChemotherapy - ClofarabineAcute myeloid leukaemiaMedDRA version: 12.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaMedDRA version: 12.1Level: LLTClassification code 10000880Term: Acute myeloid leukaemiaEUCTR2009-017347-33-DEniversity of Leipzig60
进行中(未招募)
不适用
trial evaluating the efficacy of omalizumab (Xolair ®) in idiopathic refractory severe solar urticariaEUCTR2013-004910-16-FRCentre Hospitalier régional Universitaire de Besançon
